A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy.
In a randomized, double-blind, placebo-controlled pilot study, we examined the effect of Org 2766--a corticotropin (4-9) analogue--on neurotoxicity in 28 patients with lymphoma who were treated with combination chemotherapy containing Vinca alkaloids (vincristine and vinblastine). The patients received a total dose of 12 mg of vincristine in the case of non-Hodgkin's lymphoma and a total dose of 16 mg of vincristine in the case of Hodgkin's disease. Moreover, the patients with Hodgkin's disease received a mean total dose of 84 mg of vinblastine. Subcutaneous injections of 2 mg of Org 2766 or placebo were administered to patients with non-Hodgkin's lymphoma on days 1 and 10 of each chemotherapy course and to patients with Hodgkin's disease on days 1 and 8 of each chemotherapy course. The first injection was always given before the administration of vincristine. Assessment of neurologic symptoms and signs and measurement of sensory thresholds (vibration sense and temperature sense) were performed on day 1 of the first, fourth, and sixth (or eighth) courses and 6 weeks after cessation of chemotherapy. Thirteen patients (mean age, 44.7 years) received Org 2766 and 15 patients (mean age, 54.7 years) received placebo. More symptoms occurred in the placebo group, but only numbness and autonomic complaints occurred significantly more often in the placebo group. Motor deficit and sensory disturbances were more severe and also occurred significantly more often in the placebo group. There was no difference with respect to reflex examination findings and sensory thresholds.(ABSTRACT TRUNCATED AT 250 WORDS)
van Kooten
B
B
Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
van Diemen
H A
HA
Groenhout
K M
KM
Huijgens
P C
PC
Ossenkoppele
G J
GJ
Nauta
J J
JJ
Heimans
J J
JJ
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced*; D010446:Peptide Fragments / Q000494:pharmacology*; D010865:Pilot Projects; D010919:Placebos; D012678:Sensation Disorders / Q000139:chemically induced; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use; D014748:Vinca Alkaloids / Q000009:adverse effects* / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D010446:Peptide Fragments; D010919:Placebos; D014748:Vinca Alkaloids; C013765:Org 2766; D014750:Vincristine; D014747:Vinblastine; D000324:Adrenocorticotropic Hormone